Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

azenosertib (ZN-c3)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Zentalis Pharma

Drug class:

WEE1 inhibitor

Related drugs:

‹

›

No biomarker	Endometrial Adenocarcinoma	No biomarker	Endometrial Adenocarcinoma	ZN-c3 Sensitive: B - Late Trials ZN-c3 Sensitive : B	ZN-c3 Sensitive: B - Late Trials ZN-c3 Sensitive : B
CCNE1 overexpression	Ovarian Cancer	CCNE1 overexpression	Ovarian Cancer	ZN-c3 Sensitive: C3 – Early Trials ZN-c3 Sensitive : C3	ZN-c3 Sensitive: C3 – Early Trials ZN-c3 Sensitive : C3
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + ZN-c3 Resistant: D – Preclinical trastuzumab + ZN-c3 Resistant : D	trastuzumab + ZN-c3 Resistant: D – Preclinical trastuzumab + ZN-c3 Resistant : D
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	ZN-c3 Resistant: D – Preclinical ZN-c3 Resistant : D	ZN-c3 Resistant: D – Preclinical ZN-c3 Resistant : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	ZN-c3 + ZN-c5 Sensitive: D – Preclinical ZN-c3 + ZN-c5 Sensitive : D	ZN-c3 + ZN-c5 Sensitive: D – Preclinical ZN-c3 + ZN-c5 Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	palbociclib + ZN-c3 Sensitive: D – Preclinical palbociclib + ZN-c3 Sensitive : D	palbociclib + ZN-c3 Sensitive: D – Preclinical palbociclib + ZN-c3 Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	ZN-c3 Sensitive: D – Preclinical ZN-c3 Sensitive : D	ZN-c3 Sensitive: D – Preclinical ZN-c3 Sensitive : D